An information processing device includes a first determination unit that inputs information related to total protein (TP), cholinesterase (ChE), total cholesterol (TC), creatinine (CREA), and creatine phosphokinase (CPK) to a first learning-completed model based on information related to a blood examination of a subject and outputs information related to whether thyroid stimulation hormone (TSH) of the subject is in a range for which medical treatment is needed.

The disclosure provides for a method for determining the stage of a periodontal disease by using as an index the amount of occult blood, and the number of white blood cells or a total protein concentration in the examination object obtained from the oral cavity.

A method for determining the amount of a specific analyte by photometric assays, wherein the specific analyte in a sample reacts with an analyte specific reaction partner in a reaction mixture. At least two calibration curves are generated, the first calibration curve recorded at a first wavelength is optimized for low concentrations of the specific analyte thereby maximizing the lower detection limit and, the second calibration curve recorded at a second wavelength is optimized for high concentrations of the specific analyte thereby maximizing the upper detection limit. The optimized lower detection limit and the optimized upper detection limit results in an extended dynamic range.

The present invention relates to a method for the detection of the capsid titer of an adeno-associated virus (AAV) and to a method for the determination of the ratio of full and empty capsids of an AAV by the use of an affinity matrix.

Disclosed herein are compositions and methods for determining a risk of cancer, such as head and neck squamous cell carcinoma, in a subject using a bodily fluid sample from the subject and assays for markers such as solCD44 and total protein. Also disclosed are methods of treating a subject based on said risk. Methods of determining the efficacy of a cancer treatment are also disclosed.

The present invention describes compositions and methods for treating cardiovascular disease and myocardial infarction using dipeptidyl peptidase inhibitors. Also provided are methods for increasing natriuretic peptide function by administering one or more analogues of B type natriuretic peptide that provide increased stability in the presence of prolyl-specific dipeptidyl peptidases.

A health monitoring system includes: a measurement unit that measures fluid information about a fluid in a puddle of water into which urine excreted by a user of a toilet has flowed; an analysis part that analyzes the excreted urine by assaying a fluid model formed by modeling the fluid based on the fluid information; and an estimation part that estimates a disease of the user based on excreted urine information about the excreted urine.

The invention provides reagents and methods for diagnosing kidney disease in a human or animal.

In various embodiments, provided are methods for selecting and formulating compositions for treating and maintaining the quality of skin in a select population, wherein a composition is selected for use in a personal care product based on its demonstrated biological effect to improve skin quality in the population as evidenced by one or more biomarker changes that correlate with improvement as evidenced by one or more objective measurements of skin health in the population.

Extraction and separation methods that can be used to quantify the absolute concentrations of one or more low abundance biomolecules present in biological fluids and tissues, without the need for antibody enrichment or reliance on an antibody for quantification are provided. These biomolecules can be biomarkers used to diagnose and monitor disease progression. As an example, these methods are applied to human plasma and CSF, and used to quantify Alzheimer's disease biomarkers.